Company Overview and News

 
BBI Group’s Pilbara iron ore railway ratified in parliament

2017-12-11 australianmining.com.au
Balla Balla Infrastructure Group (BBIG) has made significant progress with its Western Australia iron ore railway project, having received royal assent to become ratified as a WA act of parliament — The Railway (BBI Rail Aus Pty Ltd) Agreement 2017.
Upvote Downvote

 
BBI Group joins forces with Brockman in the Pilbara

2017-11-19 australianmining.com.au
Brockman Mining hopes to unlock the potential of its Marillana project in the Pilbara through an agreement that will give it access to BBI Group’s (BBIG) proposed iron ore infrastructure facility in the region.
Upvote Downvote

 
Ex-limo firm, Kiwi billionaire bet on iron ore with projects, mine takeovers

2016-09-27 theage.com.au
The global iron ore market is awash with supply and prices remain volatile, but a former Chinese limousine rental service and a billionaire New Zealand family are among producers and developers wagering that new mines will be needed.
Upvote Downvote

 
Ex-limo firm, Kiwi billionaire bet on iron ore with projects, mine takeovers

2016-09-27 smh.com.au
The global iron ore market is awash with supply and prices remain volatile, but a former Chinese limousine rental service and a billionaire New Zealand family are among producers and developers wagering that new mines will be needed.
Upvote Downvote

 
High Court rejects FMG appeal

2016-09-02 businessnews.com.au
Hong Kong-based Brockman Mining has continued its run of legal victories in its efforts to gain access to Fortescue Metals Group’s rail infrastructure.
Upvote Downvote

 
Morning Headlines

2016-03-29 businessnews.com.au
Listen to podcasts covering breaking news, items of interest and our Success & Leadership Series events. A wide range of topics covered by our well renowned reporters and WA business leaders. Subscribe on iTunes for updates as they happen. Click here for more
Upvote Downvote

 
Qube benefits from Brockman's maverick move on Pilbara iron ore mine

2016-03-29 theage.com.au
Brockman plans to use long road trains known as "Super Quads" to haul iron ore. Photo: West Australian Government
Upvote Downvote

 
Qube benefits from Brockman's maverick move on Pilbara iron ore mine

2016-03-29 smh.com.au
Brockman plans to use long road trains known as "Super Quads" to haul iron ore. Photo: West Australian Government
Upvote Downvote

 
Brockman in Qube deal for new mine

2016-03-24 businessnews.com.au
Listen to podcasts covering breaking news, items of interest and our Success & Leadership Series events. A wide range of topics covered by our well renowned reporters and WA business leaders. Subscribe on iTunes for updates as they happen. Click here for more
Upvote Downvote

 
Interim Report

2016-03-07 asx.com.au
Upvote Downvote

 
FMG ordered to open up Pilbara rail access for Brockman Mining

2016-02-29 abc.net.au
Junior iron ore hopeful Brockman Mining wins a legal challenge in its bid to access the rail line built by an infrastructure subsidiary of Fortescue Metals Group.
Upvote Downvote

 
Fortescue Metals Group loses appeal to block Brockman from rail

2016-02-29 smh.com.au
A WA court has dismissed Fortescue Metals Group's bid to stop a junior iron ore hopeful getting access to its Pilbara railway line.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...